Focused On-demand Library for Melatonin receptor type 1A

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P48039

UPID:
MTR1A_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P48039; A0AVC5; B0M0L2

BACKGROUND:
Melatonin receptor type 1A, with the unique identifier P48039, is crucial for the high-affinity binding of melatonin. This receptor is central to the regulation of circadian rhythms and reproductive processes, functioning through the inhibition of adenylate cyclase activity by pertussis toxin-sensitive G proteins.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Melatonin receptor type 1A offers promising avenues for therapeutic intervention. Given its regulatory role in sleep patterns and fertility, targeting this receptor could lead to innovative treatments for sleep-related disorders and reproductive challenges.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8557 of 8789